Versant Venture Management, LLC
SAN FRANCISCO, CA · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 13, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$109.1M2026 Q3
Positions8
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.100.0%
What Changed This Quarter?
Top Holdings
GLUE
Monte Rosa Therapeutics
34.8%
IPSC
Century Therapeutics
19.1%
CTNM
Contineum Therapeutics
15.9%
JBIO
Jade Biosciences
12.8%
LENZ
LENZ Therapeutics
9.4%
CRSP
CRISPR Therapeutics
7.5%
SKYE
Skye Bioscience
0.4%
Tempest Thera…
Tempest Therapeutics
0.2%
Reduced / Exited
0 reduced · 1 sold out
Skye Bioscien…EXIT
Skye Bioscience
0.9%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.